Giant coronary aneurysms in children with Kawasaki disease and major cardiac complications and dynamic follow-up

Table 5 Treatment at the onset of Kawasaki disease

Therapy at onset	Children with coronary dilatation (n = 32)	Group 1 (with giant/medium coronary artery aneurysms) (n = 13)	Group 2 (with moderate coronary dilatation) (n = 19)
Intravenous immunoglobulin	30 (94.0)	13 (100)	17 (89.0)
Glucocorticosteroids	3 (9.0)	2 (15.0)	1 (5.0)
Etanercept	1 (3.0)	1 (8.0)	0 (0)
Cyclosporine	2 (6.0)	1 (8.0)	1 (5.0)
Acetylsalicylic acid	31 (97.0)	13 (100)	18 (95.0)
Anticoagulants: LMWH or heparin (intravenous) with subsequent LMWH	12 (38.0)	7 (54.0)	5 (26.0)
Heart failure therapy at the Kawasaki disease onset
Carditonics	2 (6.0)	1 (8.0)	1 (5.0)
Diuretics	22 (69.0)	11 (85.0)	11 (58.0)
Beta-blockers	14 (44.0)	5 (38.0)	9 (47.0)
Angiotensin-converting enzyme inhibitors	7 (22.0)	5 (38.0)	2 (11.0)
Outcomes
Regression of thrombosis	6/6 (100)	6/6 (100)	0 (0)
Ischemic dilated cardiomyopathy	3 (9.4)	3 (23.0)	0 (0)

Data are presented as n (%). LMWH: Low molecular weight heparin.